Phase I/II study of intravenous and intraperitoneal paclitaxel for peritoneal metastasis after resection of pancreatic cancer refractory to gemcitabine and fluoropyrimidine chemotherapy
Not Applicable
- Conditions
- Peritoneal metastasis after resection of pancreatic cancer refractory to gemcitabine and fluoropyrimidine chemotherapy
- Registration Number
- JPRN-UMIN000016670
- Lead Sponsor
- Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 35
Inclusion Criteria
Not provided
Exclusion Criteria
Metastasis to other distant organsuch as the liver, lungs or bone; other active concomitant malignancies; other severe medical conditions; contraindication of Paclitaxel, Pregnant woman, no informed consent
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Phase-I: Dose limiting toxicity Phase-II: 2-year survival
- Secondary Outcome Measures
Name Time Method